RSS   Newsletter   Contact   Advertise with us
Post Online Media

Aytu BioScience reports two addition to board

Aytu BioScienceAytu BioScience, Inc., a specialty pharmaceutical company, announced the addition of John Donofrio, Jr. and Gary Cantrell to the company’s board of directors.
Article continues below

READ MORE Aytu BioScience names Jonathan Heath McGrael as VP, sales

Mr. Donofrio is the Chief Financial Officer and Head of North American Business Development for Merz North America, or Merz, since August 2013.

Over his 24-year career in pharmaceuticals he has a broad range of experience in consolidated financial reporting, international accounting and internal controls, budget and forecast planning, mergers and acquisitions, business development and other strategic and financial areas.

Previously, he served as interim CFO and vice president of Stiefel Global Finance, U.S. specialty business and Puerto Rico, for Stiefel, a GlaxoSmithKline plc. company (GSK). He was also the senior finance partner for the U.S. specialty business units of GSK.

Mr. Donofrio holds a degree in accounting from North Carolina State University.

Mr. Cantrell’s thirty years’ experience in the life sciences industry ranges from clinical experience as a respiratory therapist to his current executive-level consulting role with Mayne Pharma as business development executive focused on acquiring branded prescription assets for Mayne Pharma’s U.S. specialty brands division.

Prior to forming his professional consultancy, Mr. Cantrell served as CEO of Yasoo Health Inc., a global specialty nutritional company from 2007 to 2015, highlighted by the sale of its majority asset, AquADEKs, to Actavis in March 2015.

He was also president of the Catevo Group, a North Carolina-based healthcare consulting firm, and executive vice president, sales and marketing at TEAMM Pharmaceuticals, an Accentia Biopharmaceuticals company.

Mr. Cantrell started his pharmaceutical career at GSK, where he held multiple senior management positions in sales, marketing and business development over a period of 22 years.

He has served as an advisor or board member of several emerging life science companies including his role as a board member at Flexible Stenting Solutions, Inc., which was sold to Cordis, while a division of Johnson & Johnson in March 2013.

Mr. Cantrell is a graduate of Wichita State University.

 LATEST MOVES FROM Colorado 


 
 

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy